Differential subcellular distribution renders HAI-2 a less effective protease inhibitor than HAI-1 in the control of extracellular matriptase proteolytic activity

[1]  Michael D. Johnson,et al.  Aberrant regulation favours matriptase proteolysis in neoplastic B-cells that co-express HAI-2 , 2019, Journal of enzyme inhibition and medicinal chemistry.

[2]  C. Kao,et al.  Tissue distribution and subcellular localizations determine in vivo functional relationship among prostasin, matriptase, HAI-1, and HAI-2 in human skin , 2018, PloS one.

[3]  Michael D. Johnson,et al.  Matriptase shedding is closely coupled with matriptase zymogen activation and requires de novo proteolytic cleavage likely involving its own activity , 2017, PloS one.

[4]  T. Bugge,et al.  Matriptase zymogen supports epithelial development, homeostasis and regeneration , 2017, BMC Biology.

[5]  Min Liu,et al.  The crystal structure of a multidomain protease inhibitor (HAI-1) reveals the mechanism of its auto-inhibition , 2017, The Journal of Biological Chemistry.

[6]  V. Ellis,et al.  HAI‐2 stabilizes, inhibits and regulates SEA‐cleavage‐dependent secretory transport of matriptase , 2017, Traffic.

[7]  Michael D. Johnson,et al.  Selective Inhibition of Prostasin in Human Enterocytes by the Integral Membrane Kunitz-Type Serine Protease Inhibitor HAI-2 , 2017, PloS one.

[8]  J. S. Pedersen,et al.  Crystal Structure of a Two-domain Fragment of Hepatocyte Growth Factor Activator Inhibitor-1 , 2016, The Journal of Biological Chemistry.

[9]  Michael D. Johnson,et al.  Matriptase Complexes and Prostasin Complexes with HAI-1 and HAI-2 in Human Milk: Significant Proteolysis in Lactation , 2016, PloS one.

[10]  Michael D. Johnson,et al.  N-Glycan Branching Affects the Subcellular Distribution of and Inhibition of Matriptase by HAI-2/Placental Bikunin , 2015, PloS one.

[11]  Michael D. Johnson,et al.  Differential Subcellular Localization Renders HAI-2 a Matriptase Inhibitor in Breast Cancer Cells but Not in Mammary Epithelial Cells , 2015, PloS one.

[12]  F. Mulder,et al.  The solution structure of the MANEC-type domain from hepatocyte growth factor activator inhibitor-1 reveals an unexpected PAN/apple domain-type fold. , 2015, The Biochemical journal.

[13]  Michael D. Johnson,et al.  Matriptase Autoactivation Is Tightly Regulated by the Cellular Chemical Environments , 2014, PloS one.

[14]  K. Young,et al.  Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas. , 2013, The American journal of pathology.

[15]  Jette Bornholdt,et al.  Hepatocyte growth factor activator inhibitor-2 prevents shedding of matriptase. , 2013, Experimental cell research.

[16]  M. Liu,et al.  Matriptase is highly upregulated in chronic lymphocytic leukemia and promotes cancer cell invasion , 2013, Leukemia.

[17]  J. Kao,et al.  Matriptase Activation, an Early Cellular Response to Acidosis* , 2009, The Journal of Biological Chemistry.

[18]  J. P. Hobson,et al.  Regulation of cell surface protease matriptase by HAI2 is essential for placental development, neural tube closure and embryonic survival in mice , 2009, Development.

[19]  T. Bugge,et al.  Loss of matriptase suppression underlies spint1 mutation-associated ichthyosis and postnatal lethality. , 2009, The American journal of pathology.

[20]  K. Inouye,et al.  Role of the stem domain of matriptase in the interaction with its physiological inhibitor, hepatocyte growth factor activator inhibitor type I. , 2009, Journal of biochemistry.

[21]  Ming-Shyue Lee,et al.  Purification from human milk of matriptase complexes with secreted serpins: mechanism for inhibition of matriptase other than HAI-1. , 2008, American journal of physiology. Cell physiology.

[22]  R. Leduc,et al.  Mutation G827R in Matriptase Causing Autosomal Recessive Ichthyosis with Hypotrichosis Yields an Inactive Protease* , 2008, Journal of Biological Chemistry.

[23]  K. Inouye,et al.  Roles of Functional and Structural Domains of Hepatocyte Growth Factor Activator Inhibitor Type 1 in the Inhibition of Matriptase* , 2008, Journal of Biological Chemistry.

[24]  Kevin B. Walters,et al.  Live imaging of chronic inflammation caused by mutation of zebrafish Hai1 , 2007, Journal of Cell Science.

[25]  R. Dickson,et al.  Autoactivation of matriptase in vitro: requirement for biomembrane and LDL receptor domain. , 2007, American journal of physiology. Cell physiology.

[26]  A. Molinolo,et al.  Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development , 2007, Oncogene.

[27]  R. Dickson,et al.  HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. , 2005, American journal of physiology. Cell physiology.

[28]  R. Dickson,et al.  Simultaneous activation and hepatocyte growth factor activator inhibitor 1-mediated inhibition of matriptase induced at activation foci in human mammary epithelial cells. , 2005, American journal of physiology. Cell physiology.

[29]  Wei Li,et al.  Tissue Expression, Protease Specificity, and Kunitz Domain Functions of Hepatocyte Growth Factor Activator Inhibitor-1B (HAI-1B), a New Splice Variant of HAI-1* , 2003, Journal of Biological Chemistry.

[30]  R. Dickson,et al.  The Activation of Matriptase Requires Its Noncatalytic Domains, Serine Protease Domain, and Its Cognate Inhibitor* , 2003, Journal of Biological Chemistry.

[31]  S. Nakahara,et al.  Prometastatic Effect ofN-Acetylglucosaminyltransferase V Is Due to Modification and Stabilization of Active Matriptase by Adding β1–6 GlcNAc Branching* , 2002, The Journal of Biological Chemistry.

[32]  R. Dickson,et al.  Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. , 2001, European journal of biochemistry.

[33]  C. Craik,et al.  Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Johnson,et al.  Molecular Cloning of cDNA for Matriptase, a Matrix-degrading Serine Protease with Trypsin-like Activity* , 1999, The Journal of Biological Chemistry.

[35]  M. Johnson,et al.  Purification and Characterization of a Complex Containing Matriptase and a Kunitz-type Serine Protease Inhibitor from Human Milk* , 1999, The Journal of Biological Chemistry.

[36]  R. Schwartz,et al.  Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains , 1999, Immunogenetics.

[37]  N. Kitamura,et al.  Hepatocyte growth factor activator inhibitor type 2 lacking the first Kunitz-type serine proteinase inhibitor domain is a predominant product in mouse but not in human. , 1999, Biochemical and biophysical research communications.

[38]  K. Matsumoto,et al.  Purification and Cloning of Hepatocyte Growth Factor Activator Inhibitor Type 2, a Kunitz-type Serine Protease Inhibitor* , 1997, The Journal of Biological Chemistry.

[39]  R. Dickson,et al.  Characterization of a Novel, Membrane-bound, 80-kDa Matrix-degrading Protease from Human Breast Cancer Cells , 1997, The Journal of Biological Chemistry.

[40]  K. Miyazawa,et al.  Hepatocyte Growth Factor Activator Inhibitor, a Novel Kunitz-type Serine Protease Inhibitor* , 1997, The Journal of Biological Chemistry.

[41]  A. Wellstein,et al.  Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. , 1993, Cancer research.

[42]  C. Woodward,et al.  Structure of form III crystals of bovine pancreatic trypsin inhibitor. , 1987, Journal of molecular biology.

[43]  I. Kato,et al.  Protein inhibitors of proteinases. , 1980, Annual review of biochemistry.

[44]  H. Neurath,et al.  Inactivation of bovine trypsinogen and chymotrypsinogen by diisopropylphosphorofluoridate. , 1972, Proceedings of the National Academy of Sciences of the United States of America.